BACCULOW SIGNALFINANCIAL10-Q

BACCU's quarterly filing shows routine SPAC operational updates with modest declines in cash position and net income as the company continues its target search phase.

As a newly formed SPAC that commenced operations in February 2025, BACCU remains in its standard pre-acquisition phase with $203.7 million held in trust for potential business combinations. The company has progressed from formation activities to actively searching for acquisition targets, representing normal SPAC lifecycle progression.

Comparing 2025-11-12 vs 2025-08-12View on EDGAR →
FINANCIAL ANALYSIS

The company's operating cash position declined modestly from $561K to $359K while current liabilities increased by approximately 49% to $1.6M, reflecting typical SPAC operating expenses and professional fees during the target search period. Net income decreased to $1.1M from $1.9M, consistent with ongoing operational costs. The substantial trust account balance of $203.7 million remains the key financial metric, providing ample resources for a future business combination.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+48.6%
$1.1M$1.6M

Current liabilities surged 48.6% — significant near-term obligations; verify ability to meet short-term debt.

Net Income
P&L
-40.7%
$1.9M$1.1M

Net income declined 40.7% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
-36.1%
$561K$359K

Cash declined 36.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-23.3%
$658K$505K

Current assets declined 23.3% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2025-11-12
PRIOR — 2025-08-12
ADDED
As of September 30, 2025, the Company had not commenced any operations.
All activity for the period from February 10, 2025 (inception) through September 30, 2025 relates to the Company s formation, the Initial Public Offering (as defined below), and the search for a suitable target to effect the Business Combination.
Liquidity and Capital Resources As of September 30, 2025, the Company had $ 1,045,403 cash and working capital of $ 1,061,429 .
In the opinion of Company management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair statement of the financial position, operating results and cash flows for the periods presented.
The Company had $ 1,045,403 cash and no cash equivalents as of September 30, 2025.
+7 more — sign up free →
REMOVED
Unaudited Condensed Balance Sheet as of June 30, 2025 1 Unaudited Condensed Statement of Operations for the three months ended June 30, 2025 and for the period from February 10, 2025 (Inception) through June 30, 2025 2 Unaudited Condensed Statement of Changes in Shareholders Deficit for the three months ended June 30, 2025 and for the period from February 10, 2025 (Inception) through June 30, 2025 3 Unaudited Condensed Statement of Cash Flows for the period from February 10, 2025 (Inception) through June 30, 2025 4 Notes to Unaudited Condensed Financial Statements 5 Item 2.
The Company has not selected any specific Business Combination target and the Company has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any Business Combination target with respect to an initial Business Combination with the Company.
As of June 30, 2025, the Company had not commenced any operations.
All activity for the period from February 10, 2025 (inception) through June 30, 2025 relates to the Company s formation and the Initial Public Offering (as defined below).
Liquidity and Capital Resources As of June 30, 2025, the Company had $ 1,235,432 cash and working capital of $ 1,269,573 .
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →